Q2 2025 Earnings Call Transcript July 31, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is $1.46, expectations were $1.07. Operator: Good day, and welcome to the ...

Discover Bristol-Myers Squibb's Q2 2025 earnings insights: 17% growth, new partnerships, and raised guidance signal strong performance and a ...

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

An ADR is created when a bank buys shares of a foreign company outside the United States and issues a security representing shares of that company. Priced in U.S. dollars, these ADR shares trade just ...

Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

The company will pay $140.6 million to settle claims that it illegally exported products to China. Separately, Cadence posted higher revenue in the second quarter and boosted its full-year earnings ...